Cancer Drugs Fund receives boost but will no longer fund “overpriced” drugsBMJ 2014; 349 doi: http://dx.doi.org/10.1136/bmj.g5382 (Published 01 September 2014)Cite this as: BMJ 2014;349:g5382Nigel HawkesThe Cancer Drugs Fund has been...Show More Summary
From a Caltech commencement address given in 1974 Also in Surely You're Joking, Mr. Feynman! During the Middle Ages there were all kinds of crazy ideas, such as that a piece of of rhinoceros horn would increase potency. Then a method...Show More Summary
6:52 pm, August 30, 2014 Jiji Press Novartis Pharma K.K. said it has failed to report to the health ministry at least 2,579 cases of serious side effects, including a fatality, from its drugs for leukemia and other diseases even though its employees were aware of the problems. Show More Summary
I’m taking a break from blogging this week and rerunning some popular posts from the past 12 months. Click here to see the original post and comments from February 2014. Moments after yesterday's post on the booming 340B contract pharmacy...Show More Summary
I'm going to be taking an extra day of vacation before the kids start back to school, so I'm adding to the Labor Day weekend today. Blogging will resume on Tuesday, unless something gigantic happens before then. If I can come up with something appropriate, maybe I'll put up a recipe!
Here's a short video history of the FDA, courtesy of BioCentury TV. The early days, especially Harvey Wiley and the "Poison Squad", are truly wild and alarming by today's standards. But then, the products that were on the market back then were pretty alarming, too...
A reader has sent along the question: "Have any repurposed drugs actually been approved for their new indication?" And initially, I thought, confidently but rather blankly, "Well, certainly, there's... and...hmm", but then the biggest example hit me: thalidomide. Show More Summary
I’m taking a break from blogging this week and rerunning some of 2014's most popular posts. Click here to see the original post and comments from June 2014. Four of the biggest pharmacy benefit managers (PBMs)—Catamaran, CVS Caremark, Express Scripts, and Prime Therapeutics—have now released their 2013 drug trend reports. Show More Summary
Here is the updated version of the "smallest drugs" collection that I did the other day. Here are the criteria I used: the molecular weight cutoff was set, arbitrarily, at aspirin's 180. I excluded the inhaled anaesthetics, only allowing things that are oils or solids in their form of use. Show More Summary
What scientific journals can you not be bothered to keep up with? I know, sometimes it's tempting to answer "all of them", but a well-informed chemist really should watch what comes out in the better ones. But how about the not-so-better...Show More Summary
I’m taking a break from blogging this week and rerunning some of 2014's popular posts. Click here to see the original post and comments from May 2014. Last week, I attended the bigger-than-ever Armada Healthcare Specialty Pharmacy Summit...Show More Summary
There have been several analyses that have suggested that phenotypic drug discovery was unusually effective in delivering "first in class" drugs. Now comes a reworking of that question, and these authors (Jörg Eder, Richard Sedrani,Show More Summary
I’m taking a break from blogging this week and rerunning some of 2014's popular posts. Click here to see the original post and comments from February 2014. As predicted, McKesson and Rite Aid announced a new generic purchasing agreement. Show More Summary
Mentioning such a small compound as pirfenidone prompts me to put up the graphic shown below: these are the smallest commonly used drugs that I can think of. (OK, there's cocaine as a nasal anaesthetic - no, really - but that's where I draw the line at "commonly used". Show More Summary
Experimental and Clinical Cardiology used to be a reputable journal. Now it's a trash heap piled with crap. No, literally - the Ottawa Citizen newspaper has proof, thanks to reporter Tom Spears (who's an experienced hand at this). The...Show More Summary
It has been a bizarre ride for InterMune, its employees, and its investors. But now it ends with Roche buying them for $8.3 billion dollars, a sum that would have brought incredulous stares a few years ago. The deal makes sense for Roche, and it will provide investors a rationale for years as they buy into small biopharma companies - trying to pick the next InterMune, you know.
According to the 2014 U.S. Mobile App Report by Comscore, U.S. digital consumers now spend more time using mobile apps than they do on desktop computers (see chart below). "Total U.S. digital media time spent has jumped 24 percent in...Show More Summary
Specialty Pharmacy and Distribution NetworksOctober 28-29, 2014 | Philadelphia, PAwww.cbinet.com/specialtydistribution Now in its fifth year, the Specialty Pharmacy Distribution Networks Conference uniquely addresses the complexity of commercialization and market access of specialty products. Show More Summary